• Embed Doc
  • Readcast
  • Collections
  • CommentGo Back
RENAL ADVENTURES WITH IMAGING
JOEL M. TOPF, M.D.
Clinical Nephrologist
248.470.8163
T W O
E L L
The hardest month that you\u2019ll love at St John
22201 Moross Road, Detroit\u2022 telephone: 313.886.8787\u2022 fax: 313.886.4103\u2022 www.scsp.net
Introduction

The pattern of modern medical care:
\u2022The patient gets sick and presents with a set of symptoms.
\u2022The physician determines a differential of possible diagnosis
\u2022The physician orders and performs a a slate of diagnostic studies: laboratory, physical exam maneuvers, imaging

studies or procedures (biopsy, thoracentesis etc.).
\u2022After establishing a diagnosis drugs are administered and procedures performed to cure or alleviate symptoms.

A common calculation in determining the treatment is to weigh the risks of the inherent in the therapy and compare
them to the risks of the disease itself. The more severe the disease the more toxicity we are wiling to accept in the
therapy. The contemporary hospitalized patients are so ill that physicians routinely order therapies with huge de-
grees of associated morbidity: bypass surgery, chemotherapy, liver transplantation, radiation therapy; there is nearly
no limit to the amount of risk we will take to battle disease.

I believe that physicians have become so used to exposing patients to risk in the treatment phase that they do not
adjust the assessment of risk-bene\ufb01t when exposing patients to the risks inherent in diagnostic tests.

The bene\ufb01t that patients receive from undergoing a diagnostic tests are more dif\ufb01cult to pin-down than the bene\ufb01t from treatment. What bene\ufb01t does a patient gain from accurately diagnosing a self-limited, spontaneously resolving condition like post-strep GN? On the end of the scale, what bene\ufb01t does a patient gain from accurately diagnosing a fatal and untreatable condition like metastatic pancreatic cancer? Obviously patients have little gain from these pro- cedures and hence we should accept very little risk in the diagnostic work-up of these conditions.

Remember when determining acceptable risk to patients in the diagnostic phase, you should have much less risk
tolerance.

There are three different diagnostic situations where renal issues \ufb01gure prominently in this determination of risk ver- sus bene\ufb01t: the risk of contrast nephropathy with iodinated contrast agents; the risk of nephrogenic systemic sclerosis with gadolinium containing paramagnetics for MRI/MRA ; and the risk of acute renal failure with sodium phosphate for bowel prep prior to colonoscopy.

Joel M. Topf, M.D.\ue000
Noon Conference
2
Acute phosphate nephropathy: Case Report\ue000
4
CC: I\u2019m still on dialysis\ue000
4
Oral sodium phosphate solutions and nephrocalcinosis\ue000
4
Epidemiology\ue000
6
The Bronx VA\ue000
7
Henry Ford Hospital\ue000
7
Archives of Internal Medicine\ue000
8
Conclusion\ue000
8
Gadolinium and the risk of Nephrogenic Fibrosing Dermopathy\ue000
10
Case report\ue000
10
Nephrogenic Fibrosing Dermopathy\ue000
10
Gadolinium\ue000
11
Treatment\ue000
12
Conclusion\ue000
12
Strategies to Avoid Contrast Nephropathy\ue000
13
Case report\ue000
13
De\ufb01nition of contrast nephropathy\ue000
13
Preventing RCN\ue000
14
The Contrast Agents\ue000
14
Hydration Strategies\ue000
15
Half normal saline\ue000
15
Isotonic saline\ue000
16
Isotonic bicarbonate\ue000
16
Joel M. Topf, M.D.\ue000
Noon Conference
3
of 00

Leave a Comment

You must be to leave a comment.
Submit
Characters: ...
You must be to leave a comment.
Submit
Characters: ...